Abstract Details

Title Relationships between Asymmetry of Cerebral Amyloid Deposition and Cognitive Performance in Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD)

Topic Aging and Dementia

Presentation(s) P06 - (-)

Poster/Presentation
Number 032

Objective

Background BACKGROUND: The amyloid cascade hypothesis has been studied via in vivo amyloid Beta protein (AB) imaging, allowing for the examination of links between amyloid deposition and clinical aspects of AD. Relationships of lateral asymmetries of ?-amyloid deposition with cognitive deficits have not been widely studied. Correlations following expected localizations would provide support for the amyloid cascade hypothesis.

Design/Methods DESIGN/METHODS: Data from a subset of 103 participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) who had amyloid imaging with Pittsburgh compound B were included in the current study (19 healthy controls, 62 MCI, 21 AD). Amyloid density was examined in 8 regions of interest: left frontal, right frontal, left temporal, right temporal, left parietal, right parietal, left cingulate, and right cingulate. Density in these regions was examined for (1) lateral asymmetries, and (2) links with cognitive functioning using the ADNI Neuropsychological Test Battery.

Results RESULTS: Findings indicated relatively greater asymmetry in the temporal lobes than other brain regions, which did not differ by MCI or AD status. Greater amyloid deposition in the left frontal region was associated with poorer performance on Trails A (p<.05), and greater left temporal density was associated with poorer verbal memory (p<.05) and Trails B performance (p<.05). There were no other significant lateralized relationships between cognition and neuroimaging.

Conclusions CONCLUSIONS: The lack of strong interactions of asymmetry with cognitive function is in keeping with other evidence that AB deposition is not the primary element in provoking cerebral dysfunction in MCI and AD.

Authors/Disclosures
Justin T. Phillips, MD (Norton Neuroscience Institute) PRESENTER	Dr. Phillips has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie. Dr. Phillips has a non-compensated relationship as a Treasurer with Commonwealth Neurologic Society that is relevant to AAN interests or activities.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Robert P. Friedland, MD, FAAN (University of Louisville)	No disclosure on file
David H. Margolin, MD, PhD (Genzyme Corporation)	Dr. Margolin has received personal compensation for serving as an employee of uniQure, Inc.. Dr. Margolin has stock in Cerevance, Inc. Dr. Margolin has stock in Datacubed Health. Dr. Margolin has stock in uniQure, Inc.. Dr. Margolin has received intellectual property interests from a discovery or technology relating to health care.

��ɫ��

��ɫ��